Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000217972 | SCV000272681 | uncertain significance | not specified | 2015-06-11 | criteria provided, single submitter | clinical testing | The p.Asn14962Ser variant in TTN has not been previously reported in individuals with cardiomyopathy, but has been identified in 11/62924 European chromosomes b y the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org). Compu tational prediction tools and conservation analysis suggest that this variant ma y not impact the protein, though this information is not predictive enough to ru le out pathogenicity. In summary, the clinical significance of the p.Asn14962Ser variant is uncertain. |
Labcorp Genetics |
RCV000470373 | SCV000542550 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2017-08-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002429075 | SCV002740569 | uncertain significance | Cardiovascular phenotype | 2019-05-06 | criteria provided, single submitter | clinical testing | The p.N8465S variant (also known as c.25394A>G), located in coding exon 102 of the TTN gene, results from an A to G substitution at nucleotide position 25394. The asparagine at codon 8465 is replaced by serine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Ce |
RCV003437013 | SCV004152389 | uncertain significance | not provided | 2022-05-01 | criteria provided, single submitter | clinical testing | TTN: PM2, BP4 |